- Home
- NCRA vs BIAF Comparison
NCRA vs BIAF Comparison
Compare NCRA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCRA
- BIAF
- Stock Information
- Founded
- NCRA 2002
- BIAF 2014
- Country
- NCRA Taiwan
- BIAF United States
- Employees
- NCRA N/A
- BIAF N/A
- Industry
- NCRA Farming/Seeds/Milling
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NCRA Consumer Staples
- BIAF Health Care
- Exchange
- NCRA Nasdaq
- BIAF Nasdaq
- Market Cap
- NCRA 13.9M
- BIAF 12.2M
- IPO Year
- NCRA N/A
- BIAF 2022
- Fundamental
- Price
- NCRA $1.00
- BIAF $0.21
- Analyst Decision
- NCRA
- BIAF Hold
- Analyst Count
- NCRA 0
- BIAF 1
- Target Price
- NCRA N/A
- BIAF N/A
- AVG Volume (30 Days)
- NCRA 83.1K
- BIAF 799.6K
- Earning Date
- NCRA 05-06-2025
- BIAF 05-23-2025
- Dividend Yield
- NCRA N/A
- BIAF N/A
- EPS Growth
- NCRA N/A
- BIAF N/A
- EPS
- NCRA N/A
- BIAF N/A
- Revenue
- NCRA $17,013,132.00
- BIAF $9,362,022.00
- Revenue This Year
- NCRA N/A
- BIAF N/A
- Revenue Next Year
- NCRA N/A
- BIAF $19.99
- P/E Ratio
- NCRA N/A
- BIAF N/A
- Revenue Growth
- NCRA N/A
- BIAF 269.68
- 52 Week Low
- NCRA $0.70
- BIAF $0.16
- 52 Week High
- NCRA $2.09
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- NCRA 53.09
- BIAF 32.86
- Support Level
- NCRA $0.87
- BIAF $0.19
- Resistance Level
- NCRA $1.03
- BIAF $0.24
- Average True Range (ATR)
- NCRA 0.12
- BIAF 0.04
- MACD
- NCRA 0.00
- BIAF -0.02
- Stochastic Oscillator
- NCRA 52.38
- BIAF 13.80
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.